BM32

BIOLOGICAL4 trials

Sponsors

Biomay AG

Conditions

Grass Pollen AllergyHypersensitivity

Phase 1

Skin Test Study of BM32

CompletedNCT01350635

Biomay AGHypersensitivity

Start: 2011-05-31End: 2011-09-30Updated: 2015-12-18

Phase 2

Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

CompletedNCT01445002

Biomay AGGrass Pollen Allergy

Start: 2011-10-31End: 2012-10-31Updated: 2013-01-14

Phase II Study of Grass Pollen Allergy Vaccine BM32

CompletedNCT01538979

Biomay AGGrass Pollen Allergy

Start: 2012-03-31End: 2015-03-31Updated: 2015-12-18

Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response

CompletedNCT02643641

Biomay AGHypersensitivity

Start: 2016-01-31End: 2017-01-31Updated: 2017-01-19

Related Papers

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy

EBioMedicine2016-08-23136 citations